Requests that the FDA to execute an immediate administrative review and subsequent revocation of all approved New Drug Applications and Abbreviated New Drug Applications for Conjugated Equine Estrogen products—including, but not limited to, Premarin (NDA 004782)—under the authority granted by Section 505(e) of the Federal Food, Drug, and Cosmetic Act and 21 CFR § 314.150.